<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34869451</PMID><DateRevised><Year>2021</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection.</ArticleTitle><Pagination><StartPage>754667</StartPage><MedlinePgn>754667</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">754667</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2021.754667</ELocationID><Abstract><AbstractText>Clinical features of Coronavirus disease 2019 (COVID-19) are caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Acute infection management is a substantial healthcare issue, and the development of long-Covid syndrome (LCS) is extremely challenging for patients and physicians. It is associated with a variety of characteristics as impaired capillary microcirculation, chronic fatigue syndrome (CFS), proinflammatory cytokines, and functional autoantibodies targeting G-protein-coupled receptors (GPCR-AAbs). Here, we present a case report of successful healing of LCS with BC 007 (Berlin Cures, Berlin, Germany), a DNA aptamer drug with a high affinity to GPCR-AAbs that neutralizes these AAbs. A patient with a documented history of glaucoma, recovered from mild COVID-19, but still suffered from CFS, loss of taste, and impaired capillary microcirculation in the macula and peripapillary region. He was positively tested for various targeting GPCR-AAbs. Within 48 h after a single BC 007 treatment, GPCR-AAbs were functionally inactivated and remained inactive during the observation period of 4 weeks. This observation was accompanied by constant improvement of the fatigue symptoms of the patient, taste, and retinal capillary microcirculation. Therefore, the removal of GPCR-AAb might ameliorate the characteristics of the LCD, such as capillary impairment, loss of taste, and CFS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Hohberger, Harrer, Mardin, Kruse, Hoffmanns, Rogge, Heltmann, Moritz, Szewczykowski, Schottenhamml, Kr&#xe4;ter, Bergua, Zenkel, Gie&#xdf;l, Schl&#xf6;tzer-Schrehardt, L&#xe4;mmer, Herrmann, Haberland, G&#xf6;ttel, M&#xfc;ller and Wallukat.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hohberger</LastName><ForeName>Bettina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Max-Planck-Zentrum f&#xfc;r Physik und Medizin, Max Planck Institute for the Science of Light, Erlangen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine 3, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mardin</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kruse</LastName><ForeName>Friedrich</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffmanns</LastName><ForeName>Jakob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogge</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heltmann</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moritz</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szewczykowski</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schottenhamml</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kr&#xe4;ter</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Max-Planck-Zentrum f&#xfc;r Physik und Medizin, Max Planck Institute for the Science of Light, Erlangen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine 3, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergua</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zenkel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gie&#xdf;l</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schl&#xf6;tzer-Schrehardt</LastName><ForeName>Ursula</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xe4;mmer</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Max-Planck-Zentrum f&#xfc;r Physik und Medizin, Max Planck Institute for the Science of Light, Erlangen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine 3, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haberland</LastName><ForeName>Annekathrin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Berlin Cures GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;ttel</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Berlin Cures GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Berlin Cures GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallukat</LastName><ForeName>Gerd</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Berlin Cures GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BC 007</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">OCT angiography</Keyword><Keyword MajorTopicYN="N">chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">functional GPCR autoantibodies</Keyword><Keyword MajorTopicYN="N">glaucoma</Keyword><Keyword MajorTopicYN="N">long-COVID syndrome</Keyword></KeywordList><CoiStatement>BH and CM: Heidelberg Engineering. AH, PG, JM, and GW employed by Berlin Cures GmbH, shareholders of Berlin Cures Holding AG, the holding company of Berlin Cures. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34869451</ArticleId><ArticleId IdType="pmc">PMC8637609</ArticleId><ArticleId IdType="doi">10.3389/fmed.2021.754667</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rodriguez Y, Novelli L, Rojas M, De Santis M, Acosta-Ampudia Y, Monsalve DM, et al. . Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun. (2020) 114:102506. 10.1016/j.jaut.2020.102506</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102506</ArticleId><ArticleId IdType="pmc">PMC7296326</ArticleId><ArticleId IdType="pubmed">32563547</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpert G, Shoenfeld Y. SARS-CoV-2, the autoimmune virus. Autoimmun Rev. (2020) 19:102695. 10.1016/j.autrev.2020.102695</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102695</ArticleId><ArticleId IdType="pmc">PMC7598743</ArticleId><ArticleId IdType="pubmed">33130000</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P, Caraffa A, Gallenga CE, Ross R, Kritas SK, Frydas I, et al. . IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra). J Biol Regul Homeost Agents. (2020) 34:1623&#x2013;7. 10.23812/20-34-4EDIT-65</Citation><ArticleIdList><ArticleId IdType="doi">10.23812/20-34-4EDIT-65</ArticleId><ArticleId IdType="pubmed">32744052</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P, Caraffa A, Tete G, Gallenga CE, Ross R, Kritas SK, et al. . Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19. J Biol Regul Homeost Agents. (2020) 34:1629&#x2013;32. 10.23812/20-2EDIT</Citation><ArticleIdList><ArticleId IdType="doi">10.23812/20-2EDIT</ArticleId><ArticleId IdType="pubmed">32945158</ArticleId></ArticleIdList></Reference><Reference><Citation>Leppkes M, Knopf J, Naschberger E, Lindemann A, Singh J, Herrmann I, et al. . Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine. (2020) 58:102925. 10.1016/j.ebiom.2020.102925</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102925</ArticleId><ArticleId IdType="pmc">PMC7397705</ArticleId><ArticleId IdType="pubmed">32745993</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Conti P. COVID-19 and multisystem inflammatory syndrome, or is it mast cell activation syndrome? J Biol Regul Homeost Agents. (2020) 34:1633&#x2013;6. 10.23812/20-EDIT3</Citation><ArticleIdList><ArticleId IdType="doi">10.23812/20-EDIT3</ArticleId><ArticleId IdType="pubmed">33023287</ArticleId></ArticleIdList></Reference><Reference><Citation>Janiuk K, Jablonska E, Garley M. Significance of NETs formation in COVID-19. Cells. (2021) 10:151. 10.3390/cells10010151</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10010151</ArticleId><ArticleId IdType="pmc">PMC7828704</ArticleId><ArticleId IdType="pubmed">33466589</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, Furst J, Schulze-Rothe S, Wallukat A, et al. . Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. (2021) 4:100100. 10.1016/j.jtauto.2021.100100</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrishami M, Emamverdian Z, Shoeibi N, Omidtabrizi A, Daneshvar R, Saeidi Rezvani T, et al. . Optical coherence tomography angiography analysis of the retina in patients recovered from COVID-19: a case-control study. Can J Ophthalmol. (2021) 56:24&#x2013;30. 10.1016/j.jcjo.2020.11.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcjo.2020.11.006</ArticleId><ArticleId IdType="pmc">PMC7666612</ArticleId><ArticleId IdType="pubmed">33249111</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonas JB, Gusek GC, Naumann GO. Optic disc morphometry in chronic primary open-angle glaucoma. I Morphometric intrapapillary characteristics. Graefes Arch Clin Exp Ophthalmol. (1988) 226:522&#x2013;30. 10.1007/BF02169199</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02169199</ArticleId><ArticleId IdType="pubmed">3209079</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonas JB, Gusek GC, Naumann GO. Optic disc morphometry in chronic primary open-angle glaucoma. II Correlation of the intrapapillary morphometric data to visual field indices. Graefes Arch Clin Exp Ophthalmol. (1988) 226:531&#x2013;8. 10.1007/BF02169200</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02169200</ArticleId><ArticleId IdType="pubmed">3061878</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Wollenberger A. Effects of the serum gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic beta adrenoceptor function in cultured neonatal rat heart myocytes. Biomed Biochim Acta. (1987) 46:S634&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2449194</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton EA, He XY, Denorme F, Campbell RA, Ng D, Salvatore SP, et al. . Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. (2020) 136:1169&#x2013;79. 10.1182/blood.2020007008</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020007008</ArticleId><ArticleId IdType="pmc">PMC7472714</ArticleId><ArticleId IdType="pubmed">32597954</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. . Endothelial cell infection and endotheliitis in COVID-19. Lancet. (2020) 395:1417&#x2013;8. 10.1016/S0140-6736(20)30937-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. . Diverse functional autoantibodies in patients with COVID-19. Nature. (2021) 595:283&#x2013;8. 10.1038/s41586-021-03631-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P, Cifone MG, Alesse E, Reale M, Fieschi C, Dinarello CA. In vitro enhanced thromboxane B2 release by polymorphonuclear leukocytes and macrophages after treatment with human recombinant interleukin 1. Prostaglandins. (1986) 32:111&#x2013;5. 10.1016/0090-6980(86)90151-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-6980(86)90151-6</ArticleId><ArticleId IdType="pubmed">3489956</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M, Anders HJ, Bilyy R, Bowlin GL, Daniel C, De Lorenzo R, et al. . Patients with COVID-19: in the dark-NETs of neutrophils. Cell Death Differ. (2021) 10.1038/s41418-021-00805-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-021-00805-z</ArticleId><ArticleId IdType="pmc">PMC8142290</ArticleId><ArticleId IdType="pubmed">34031543</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H, Townsend L, Morrin H, Ahmad A, Comerford C, Karampini E, et al. . Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost. (2021) 19:2546&#x2013;53. 10.1111/jth.15490</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15490</ArticleId><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Han T, Chen J, Hou C, Hua L, He S, et al. . Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin Transl Sci. (2020) 13:1077&#x2013;86. 10.1111/cts.12805</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12805</ArticleId><ArticleId IdType="pmc">PMC7264560</ArticleId><ArticleId IdType="pubmed">32315487</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. . Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. (2020) 370:eabd4585. 10.1126/science.abd4585</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell J, Zhang M, Hwang T, Bailey S, Wilson D, Jia Y, et al. . Detailed vascular anatomy of the human retina by projection-resolved optical coherence tomography angiography. Sci Rep. (2017) 7:42201. 10.1038/srep42201</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42201</ArticleId><ArticleId IdType="pmc">PMC5301488</ArticleId><ArticleId IdType="pubmed">28186181</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan ML, Vasudevan NT, Naga Prasad SV. Proinflammatory cytokines mediate GPCR dysfunction. J Cardiovasc Pharmacol. (2017) 70:61&#x2013;73. 10.1097/FJC.0000000000000456</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FJC.0000000000000456</ArticleId><ArticleId IdType="pmc">PMC5483210</ArticleId><ArticleId IdType="pubmed">28763371</ArticleId></ArticleIdList></Reference><Reference><Citation>Junemann A, Hohberger B, Rech J, Sheriff A, Fu Q, Schlotzer-Schrehardt U, et al. . Agonistic autoantibodies to the beta2-Adrenergic receptor involved in the pathogenesis of open-angle glaucoma. Front Immunol. (2018) 9:145. 10.3389/fimmu.2018.00145</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00145</ArticleId><ArticleId IdType="pmc">PMC5816038</ArticleId><ArticleId IdType="pubmed">29483909</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohberger B, Worn M, Lammer R, Herrmann M, Mardin CY, Kruse FE, et al. . Agonistic &#x3b2;2-adrenergic receptor autoantibodies characterize the aqueous humor of patients with primary and secondary open-angle glaucoma. Invest Ophthalmol Vis Sci. (2020) 61. 10.3389/fimmu.2021.550236</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.550236</ArticleId><ArticleId IdType="pmc">PMC8132703</ArticleId><ArticleId IdType="pubmed">34025634</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu ML, Herlitz H, Schulze W, Wallukat G, Micke P, Eftekhari P, et al. . Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens. (2000) 18:945&#x2013;53. 10.1097/00004872-200018070-00017</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004872-200018070-00017</ArticleId><ArticleId IdType="pubmed">10930193</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Neichel D, Nissen E, Homuth V, Luft FC. Agonistic autoantibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia. Can J Physiol Pharmacol. (2003) 81:79&#x2013;83. 10.1139/y02-160</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/y02-160</ArticleId><ArticleId IdType="pubmed">12710518</ArticleId></ArticleIdList></Reference><Reference><Citation>Loebel M, Grabowski P, Heidecke H, Bauer S, Hanitsch LG, Wittke K, et al. . Antibodies to beta adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain Behav Immun. (2016) 52:32&#x2013;9. 10.1016/j.bbi.2015.09.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2015.09.013</ArticleId><ArticleId IdType="pubmed">26399744</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukitsch I, Kehr J, Chaykovska L, Wallukat G, Nieminen-Kelha M, Batuman V, et al. . Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies. Transplantation. (2012) 94:8&#x2013;13. 10.1097/TP.0b013e3182529bb7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0b013e3182529bb7</ArticleId><ArticleId IdType="pubmed">22691955</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberland A, Holtzhauer M, Schlichtiger A, Bartel S, Schimke I, Muller J, et al. . Aptamer BC 007 - A broad spectrum neutralizer of pathogenic autoantibodies against G-protein-coupled receptors. Eur J Pharmacol. (2016) 789:37&#x2013;45. 10.1016/j.ejphar.2016.06.061</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2016.06.061</ArticleId><ArticleId IdType="pubmed">27375076</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller J, Haberland A, Wallukat G, Becker N, Wenzel K, G&#xf6;ttel P, et al. . The DNA-Based Drug BC 007 neutralizes agonistically acting autoantibodies directed against G protein-coupled receptors Successful mode of action demonstrated in clinical phase 1 trial. Chimica Oggi. (2019) 37.</Citation></Reference><Reference><Citation>Haberland A, Krylova O, Nikolenko H, Gottel P, Dallmann A, Muller J, et al. . Aptamer BC 007's affinity to specific and less-specific anti-SARS-CoV-2 neutralizing antibodies. Viruses. (2021) 13:932. 10.3390/v13050932</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13050932</ArticleId><ArticleId IdType="pmc">PMC8157297</ArticleId><ArticleId IdType="pubmed">34069827</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel K, Schulze-Rothe S, Muller J, Wallukat G, Haberland A. Difference between &#x3b2;1-adrenoceptor autoantibodies of human and animal origin-Limitations detecting &#x3b2;1-adrenoceptor autoantibodies using peptide based ELISA technology. PLoS ONE. (2018) 13:e0192615. 10.1371/journal.pone.0192615</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0192615</ArticleId><ArticleId IdType="pmc">PMC5806878</ArticleId><ArticleId IdType="pubmed">29425252</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Schimke I. Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases. Semin Immunopathol. (2014) 36:351&#x2013;63. 10.1007/s00281-014-0425-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-014-0425-9</ArticleId><ArticleId IdType="pubmed">24777744</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosari S, Hohberger B, Theelke L, Sari H, Lucio M, Mardin CY. OCT Angiography: measurement of retinal macular microvasculature with spectralis II OCT angiography - reliability and reproducibility. Ophthalmologica. (2020) 243:75&#x2013;84. 10.1159/000502458</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000502458</ArticleId><ArticleId IdType="pubmed">31509842</ArticleId></ArticleIdList></Reference><Reference><Citation>Mardin C, Schottenhamml J, Maier A, Fassihi Dehkordi S, M&#xfc;ller M, Hohberger B. APSifyed Bruch's membrane opening (BMO) based peripapillary OCT-A analysis. In: ARVO IOVS (2021) 62:3369.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohberger B, Ganslmayer M, Lucio M, Kruse F, Hoffmanns J, Rogge L, et al. . Retinal microcirculation as correlate of a systemic capillary impairment after SARS-CoV-2 infection. Front Med. (2021) 8:676554. 10.3389/fmed.2021.676554</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.676554</ArticleId><ArticleId IdType="pmc">PMC8299003</ArticleId><ArticleId IdType="pubmed">34307408</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohberger B, Hosari S, Wallukat G, Kunze R, Krebs J, Muller M, et al. . Agonistic autoantibodies against &#x3b2;2-adrenergic receptor influence retinal microcirculation in glaucoma suspects and patients. PLoS ONE. (2021) 16:e0249202. 10.1371/journal.pone.0249202</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0249202</ArticleId><ArticleId IdType="pmc">PMC8104926</ArticleId><ArticleId IdType="pubmed">33961631</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>